D
EyePoint Pharmaceuticals, Inc.
EYPT
$4.13
-$0.49-10.61%
D
Sell
9/8/2023Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 9/8/2023 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 438.72% from -$16.84M to $57.02M, and total revenue increased 18.51% from $7.68M to $9.11M.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 9/8/2023 due to a major increase in the total return index, growth index and volatility index. Operating cash flow increased 438.72% from -$16.84M to $57.02M, and total revenue increased 18.51% from $7.68M to $9.11M.
E
Sell
7/31/2023Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D- on 7/31/2023 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.42 to 0.45.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D- on 7/31/2023 due to a decline in the valuation index and solvency index. Debt to equity increased from 0.42 to 0.45.
D
Sell
4/17/2023Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 4/17/2023 due to an increase in the volatility index and total return index.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 4/17/2023 due to an increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
3/13/2023Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 3/13/2023 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.4933 to -$1.1633, debt to equity increased from 0.29 to 0.42, and EBIT declined 25.21% from -$18.4M to -$23.04M.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 3/13/2023 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.4933 to -$1.1633, debt to equity increased from 0.29 to 0.42, and EBIT declined 25.21% from -$18.4M to -$23.04M.
D
Sell
2/9/2023Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from E+ on 02/09/2023.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.26 to 0.29, and the quick ratio declined from 5.8 to 5.2.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to E+ from D on 2/8/2023 due to a significant decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.26 to 0.29, and the quick ratio declined from 5.8 to 5.2.
D
Sell
6/15/2022Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D from D+ on 6/15/2022 due to a decline in the volatility index.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D from D+ on 6/15/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D+ from D- on 5/16/2022 due to an increase in the total return index.
D
Sell
5/13/2022Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and growth index. The quick ratio declined from 9.72 to 6.58, operating cash flow declined 20.94% from -$16.67M to -$20.16M, and debt to equity increased from 0.2 to 0.24.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and growth index. The quick ratio declined from 9.72 to 6.58, operating cash flow declined 20.94% from -$16.67M to -$20.16M, and debt to equity increased from 0.2 to 0.24.
D
Sell
5/5/2022Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and volatility index.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and volatility index.
D
Sell
4/20/2022Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index.
D
Sell
3/29/2022Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D from D+ on 3/29/2022 due to a noticeable decline in the total return index and valuation index.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D from D+ on 3/29/2022 due to a noticeable decline in the total return index and valuation index.
D
Sell
1/25/2022Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D+ from D on 1/25/2022 due to an increase in the valuation index and volatility index.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D+ from D on 1/25/2022 due to an increase in the valuation index and volatility index.
D
Sell
11/23/2021Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 11/23/2021.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 11/23/2021.
D
Sell
11/8/2021Downgrade
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index. Earnings per share declined from -$0.3482 to -$0.5804, and EBIT declined 39.48% from -$10.98M to -$15.31M.
EyePoint Pharmaceuticals, Inc. (EYPT) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index. Earnings per share declined from -$0.3482 to -$0.5804, and EBIT declined 39.48% from -$10.98M to -$15.31M.
D
Sell
5/1/2020Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 5/1/2020 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 244.08% from $2.51M to $8.63M, EBIT increased 36.1% from -$14.06M to -$8.99M, and earnings per share increased from -$0.1463 to -$0.0976.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D from D- on 5/1/2020 due to a major increase in the growth index, volatility index and total return index. Total revenue increased 244.08% from $2.51M to $8.63M, EBIT increased 36.1% from -$14.06M to -$8.99M, and earnings per share increased from -$0.1463 to -$0.0976.
D
Sell
4/24/2018Upgraded
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 4/24/2018 due to an increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.83 to 3.1.
EyePoint Pharmaceuticals, Inc. (EYPT) was upgraded to D- from E+ on 4/24/2018 due to an increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.83 to 3.1.
E
Sell
1/16/2018Downgrade
pSivida Corp. (PSDV) was downgraded to E+ from D- on 1/16/2018 due to a decline in the valuation index and total return index.
pSivida Corp. (PSDV) was downgraded to E+ from D- on 1/16/2018 due to a decline in the valuation index and total return index.
D
Sell
12/26/2017Upgraded
pSivida Corp. (PSDV) was upgraded to D- from E+ on 12/26/2017 due to an increase in the valuation index.
pSivida Corp. (PSDV) was upgraded to D- from E+ on 12/26/2017 due to an increase in the valuation index.
E
Sell
12/5/2017Downgrade
pSivida Corp. (PSDV) was downgraded to E+ from D- on 12/5/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Total revenue declined 45.08% from $701 to $385, operating cash flow declined 34.05% from -$4.45M to -$5.97M, and the quick ratio declined from 3.24 to 2.83.
pSivida Corp. (PSDV) was downgraded to E+ from D- on 12/5/2017 due to a noticeable decline in the growth index, valuation index and solvency index. Total revenue declined 45.08% from $701 to $385, operating cash flow declined 34.05% from -$4.45M to -$5.97M, and the quick ratio declined from 3.24 to 2.83.
D
Sell
2/10/2017Upgraded
pSivida Corp. (PSDV) was upgraded to D- from E+ on 2/10/2017 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 2,055.6% from $277 to $5.97M, earnings per share increased from -$0.2096 to -$0.002, and EBIT increased 98.61% from -$6.75M to -$94.
pSivida Corp. (PSDV) was upgraded to D- from E+ on 2/10/2017 due to a significant increase in the growth index, solvency index and valuation index. Total revenue increased 2,055.6% from $277 to $5.97M, earnings per share increased from -$0.2096 to -$0.002, and EBIT increased 98.61% from -$6.75M to -$94.
E
Sell
1/12/2017Downgrade
pSivida Corp. (PSDV) was downgraded to E+ from D- on 1/12/2017 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 49.21% from -$4.35M to -$6.49M, earnings per share declined from -$0.1879 to -$0.2096, and total revenue declined 8.88% from $304 to $277.
pSivida Corp. (PSDV) was downgraded to E+ from D- on 1/12/2017 due to a major decline in the total return index, volatility index and growth index. Operating cash flow declined 49.21% from -$4.35M to -$6.49M, earnings per share declined from -$0.1879 to -$0.2096, and total revenue declined 8.88% from $304 to $277.
D
Sell
3/11/2016Downgrade
pSivida Corp. (PSDV) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from -$0.17 to -$0.18, and EBIT declined 5.1% from -$4.98M to -$5.24M.
pSivida Corp. (PSDV) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Earnings per share declined from -$0.17 to -$0.18, and EBIT declined 5.1% from -$4.98M to -$5.24M.
D
Sell
11/13/2015Downgrade
pSivida Corp. (PSDV) was downgraded to D from B on 11/13/2015 due to a significant decline in the growth index, valuation index and efficiency index. Total capital declined 19.45% from $23.37M to $18.82M, EBIT declined 4.15% from -$5.2M to -$4.98M, and net income declined 4.14% from -$5.15M to -$4.93M.
pSivida Corp. (PSDV) was downgraded to D from B on 11/13/2015 due to a significant decline in the growth index, valuation index and efficiency index. Total capital declined 19.45% from $23.37M to $18.82M, EBIT declined 4.15% from -$5.2M to -$4.98M, and net income declined 4.14% from -$5.15M to -$4.93M.
B
Buy
9/11/2015Upgraded
pSivida Corp. (PSDV) was upgraded to B from B- on 9/11/2015 due to a noticeable increase in the growth index. Total revenue increased 24.7% from $328 to $409, earnings per share increased from -$0.17 to -$0.1771, and EBIT increased 2.93% from -$5.05M to -$5.2M.
pSivida Corp. (PSDV) was upgraded to B from B- on 9/11/2015 due to a noticeable increase in the growth index. Total revenue increased 24.7% from $328 to $409, earnings per share increased from -$0.17 to -$0.1771, and EBIT increased 2.93% from -$5.05M to -$5.2M.
B
Buy
7/13/2015Downgrade
pSivida Corp. (PSDV) was downgraded to B- from B on 7/13/2015 due to a large decline in the solvency index, valuation index and growth index. Operating cash flow declined 118.61% from $21.25M to -$3.95M, total revenue declined 37.04% from $521 to $328, and the quick ratio declined from 16.02 to 14.47.
pSivida Corp. (PSDV) was downgraded to B- from B on 7/13/2015 due to a large decline in the solvency index, valuation index and growth index. Operating cash flow declined 118.61% from $21.25M to -$3.95M, total revenue declined 37.04% from $521 to $328, and the quick ratio declined from 16.02 to 14.47.
B
Buy
2/17/2015Upgraded
pSivida Corp. (PSDV) was upgraded to B from B- on 2/17/2015 due to a noticeable increase in the volatility index and efficiency index.
pSivida Corp. (PSDV) was upgraded to B from B- on 2/17/2015 due to a noticeable increase in the volatility index and efficiency index.
B
Buy
2/4/2015Downgrade
pSivida Corp. (PSDV) was downgraded to B- from B on 2/4/2015 due to a decline in the volatility index.
pSivida Corp. (PSDV) was downgraded to B- from B on 2/4/2015 due to a decline in the volatility index.
B
Buy
1/20/2015Upgraded
pSivida Corp. (PSDV) was upgraded to B from B- on 1/20/2015 due to an increase in the volatility index and valuation index.
pSivida Corp. (PSDV) was upgraded to B from B- on 1/20/2015 due to an increase in the volatility index and valuation index.
B
Buy
1/5/2015Downgrade
pSivida Corp. (PSDV) was downgraded to B- from B on 1/5/2015 due to a noticeable decline in the volatility index and valuation index.
pSivida Corp. (PSDV) was downgraded to B- from B on 1/5/2015 due to a noticeable decline in the volatility index and valuation index.
B
Buy
11/10/2014Upgraded
pSivida Corp. (PSDV) was upgraded to B from D on 11/10/2014 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 8,566.78% from $292 to $25.31M, total capital increased 139.9% from $14.92M to $35.8M, and operating cash flow increased 43.41% from -$2.79M to -$3.99M.
pSivida Corp. (PSDV) was upgraded to B from D on 11/10/2014 due to a significant increase in the valuation index, growth index and efficiency index. Total revenue increased 8,566.78% from $292 to $25.31M, total capital increased 139.9% from $14.92M to $35.8M, and operating cash flow increased 43.41% from -$2.79M to -$3.99M.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
